ERBB2 AMPLIFICATION LEVEL AND PTPN2 GAIN AS POTENTIAL PROGNOSTIC FACTORS IN METASTATIC HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB

被引：0
|
作者：
Ellegard, Sander [1 ]
Veenstra, Cynthia [1 ]
Perez-Tenorio, Giseh [1 ]
Hallbeck, Anna-Lotta [1 ]
Elander, Nils [1 ]
Stal, Olle [1 ]
机构：
[1] Univ Hosp Linkoping, Oncol, Linkoping, Sweden
来源：
BREAST | 2017年 / 36卷
关键词：
D O I：
10.1016/S0960-9776(17)30690-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO71
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [31] Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
    Caroline Rönnlund
    Emmanouil G. Sifakis
    Caroline Schagerholm
    Qiao Yang
    Emelie Karlsson
    Xinsong Chen
    Theodoros Foukakis
    Jodi Weidler
    Michael Bates
    Irma Fredriksson
    Stephanie Robertson
    Johan Hartman
    Breast Cancer Research, 26
  • [32] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Nie, Tina
    Blair, Hannah A.
    TARGETED ONCOLOGY, 2023, 18 (03) : 463 - 470
  • [33] Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer
    Rastogi, Priya
    Davidson, Nancy E.
    ONKOLOGIE, 2010, 33 (8-9): : 420 - 421
  • [34] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [35] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer
    Hooge, MNLD
    Perik, PJ
    Gietema, JA
    Jager, PL
    Jonkman, S
    Kosterink, JGW
    Van Veldhuisen, DJJ
    Van der Graaf, WTA
    Sleijfer, DTH
    De Vries, EGE
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 210S - 210S
  • [37] Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
    Jeyakumar, Alwin
    Younis, Tallal
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [38] Very long response with trastuzumab for metastatic Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1002 - 1003
  • [39] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [40] Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond
    Zardavas, Dimitrios
    Pugliano, Lina
    Ades, Felipe
    Bozovic-Spasojevic, Ivana
    Capelan, Marta
    de Azambuja, Evandro
    BREAST CANCER MANAGEMENT, 2012, 1 (03) : 217 - 233
12345